Both high expression of pyruvate kinase M2 and vascular endothelial growth factor-C predicts poorer prognosis in human breast cancer

International Journal of Clinical and Experimental Pathology

Volumn 8, Issue 7, 2015, Pages 8028-8037

  Lin, Yang ^a   Liu, Fangfang ^a   Fan, Yu ^a   Qian, Xiaolong ^a   Lang, Ronggang ^a   Gu, Feng ^a   Gu, Jun ^b   Fu, Li ^a  

^a TIANJIN MEDICAL UNIVERSITY   (China)

^b STATE UNIVERSITY OF NEW YORK   (United States)

Author keywords

Breast cancer; Pyruvate kinase M2; vascular endothelial growth factor C

Indexed keywords

CARRIER PROTEIN; MEMBRANE PROTEIN; MESSENGER RNA; THYROID HORMONE; THYROID HORMONE-BINDING PROTEINS; TUMOR MARKER; VASCULOTROPIN C; VEGFC PROTEIN, HUMAN;

ADULT; BREAST NEOPLASMS; CANCER GRADING; CANCER STAGING; CARCINOMA, DUCTAL, BREAST; DISEASE FREE SURVIVAL; ENZYMOLOGY; FEMALE; GENE EXPRESSION REGULATION; GENETIC TRANSFECTION; GENETICS; HUMAN; IMMUNOHISTOCHEMISTRY; KAPLAN MEIER METHOD; LYMPH NODE METASTASIS; METABOLISM; MIDDLE AGED; MORTALITY; PATHOLOGY; PROPORTIONAL HAZARDS MODEL; RISK FACTOR; RNA INTERFERENCE; TIME FACTOR; TUMOR CELL LINE; UPREGULATION;

ADULT; BIOMARKERS, TUMOR; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CARRIER PROTEINS; CELL LINE, TUMOR; DISEASE-FREE SURVIVAL; FEMALE; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; LYMPHATIC METASTASIS; MEMBRANE PROTEINS; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM STAGING; PROPORTIONAL HAZARDS MODELS; RISK FACTORS; RNA INTERFERENCE; RNA, MESSENGER; THYROID HORMONES; TIME FACTORS; TRANSFECTION; UP-REGULATION; VASCULAR ENDOTHELIAL GROWTH FACTOR C;

EID: 85013001588     PISSN: None     EISSN: 19362625     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Warburg O. On the origin of cancer cells. Science 1956; 123: 309-314.
2. Christofk HR, Vander Heiden MG, Wu N, Asa-Ra JM, Cantley LC. Pyruvate kinase M2 is a ph-osphotyrosine-binding protein. Nature 2008; 452: 181-6.
3. Christofk HR, Vander Heiden MG, Harris MH, Ramanathan A, Gerszten RE, Wei R, Fleming MD, Schreiber SL, Cantley LC. The M2 spli-ce isoform of pyruvate kinase is important for cancer metabolism and tumour growth. Nature 2008; 452: 230-233.
4. Mazurek. Pyruvate kinase type M2: a key regulator of the metabolic budget system in tumor cells. Int J Biochem Cell Biol 2011; 43: 969-980.
5. Chen L, Shi Y, Liu S, Cao Y, Wang X, Tao Y. PKM2: the thread linking energy metabolism reprogramming with epigenetics in cancer. Int J Mol Sci 2014; 15: 11435-45.
6. Tamada M, Suematsu M, Saya H. Pyruvate kinase M2: multiple faces for conferring benefits on cancer cells. Clin Cancer Res 2012; 18: 5554-61.
7. Mohammed RA, Green A, El-Shikh S, Paish EC, Ellis IO, Martin SG. Prognostic significance of vascular endothelial cell growth factors-A,-C and-D in breast cancer and their relationship with angio-and lymphangiogenesis. Br J Cancer 2007; 96: 1092-1100.
8. Nakamura Y, Yasuoka H, Tsujimoto M, Imabun S, Nakahara M, Nakao K, Nakamura M, Mori I, Kakudo K. Lymph vessel density correlates wi-th nodal status, VEGF-C expression, and prognosis in breast cancer. Breast Cancer Res Treat 2005; 91: 125-132.
9. Jiang K, He B, Lai L, Chen Q, Liu Y, Guo Q, Wang Q. Cyclosporine A inhibits breast cancer cell growth by downregulating the expression of pyruvate kinase subtype M2. Int J Mol Med 2012; 30: 302-8.
10. Wang CA, Harrell JC, Iwanaga R, Jedlicka P, Ford HL. Vascular endothelial growth factor C promotes breast cancer progression via a novel antioxidant mechanism that involves regulation of superoxide dismutase 3. Breast Cancer Res 2014; 16: 462.
11. Elston CW, Ellis IO. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 2002; 41: 154-61.
12. Noguchi T, Yamada K, Inoue H, Matsuda T, Tanaka T. The L-and R-type isozymes of rat py ruvate kinase are produced from a single gene by use of different promoters. J Biol Chem 1987; 262: 14366-14371.
13. David CJ, Chen M, Assanah M, Canoll P, Manley JL. HnRNP proteins controlled by c-Myc deregulate pyruvate kinase mRNA splicing in cancer. Nature 2010; 463: 364-368.
14. Cairns RA, Harris IS, Mak TW. Regulation of cancer cell metabolism. Nat Rev Cancer 2011; 11: 85-95.
15. Hu W, Lu SX, Li M, Zhang C, Liu LL, Fu J, Jin JT, Luo RZ, Zhang CZ, Yun JP. Pyruvate kinase M2 prevents apoptosis via modulating Bim stabi-lity and associates with poor outcome in he-patocellular carcinoma. Oncotarget 2015; 6: 6570-83.
16. Zhang X, He C, He C, Chen B, Liu Y, Kong M, Wang C, Lin L, Dong Y, Sheng H. Nuclear PKM2 expression predicts poor prognosis in patients with esophageal squamous cell carcinoma. Pathol Res Pract 2013; 209: 510-5.
17. Li J, Yang Z, Zou Q, Yuan Y, Li J, Liang L, Zeng G, Chen S. PKM2 and ACVR 1C are prognostic markers for poor prognosis of gallbladder cancer. Clin Transl Oncol 2014; 16: 200-7.
18. Noel Weidner, Joseph P. Semple, William R. Welch and Judah Folkman. Tumor Angiogenesis and Metastasis-Correlation in Invasive Breast Carcinoma. N Engl J Med 1991; 324: 1-8.
19. Chien MH, Lee LM, Hsiao M, Wei LH, Chen CH, Lai TC, Hua KT, Chen MW, Sun CM, Kuo ML. Inhibition of Metastatic Potential in Breast Carcinoma In Vivo and In Vitro through Targeting VEGFRs and FGFRs. Evid Based Complement Alternat Med 2013; 2013: 718380.
20. Omoto I, Matsumoto M, Okumura H, Uchikado Y, Setoyama T, Kita Y, Owaki T, Kijima Y, Shinchi H, Ishigami S, Ueno S, Natsugoe S. Expression of vascular endothelial growth factor-C and vascular endothelial growth factor receptor-3 in esophageal squamous cell carcinoma. Oncol Lett 2014; 7: 1027-1032.
21. Li L, Zhang Y, Qiao J, Yang JJ, Liu ZR. Pyruvate kinase M2 in blood circulation facilitates tumor growth by promoting angiogenesis. J Biol Chem 2014; 289: 25812-21.
22. Xu Q, Liu LZ, Yin Y, He J, Li Q, Qian X, You Y, Lu Z, Peiper SC, Shu Y, Jiang BH. Regulatory circuit of PKM2/NF-κB/miR-148a/152-modulated tumor angiogenesis and cancer progression. Oncogene 2015; [Epub ahead of print].
23. Ni X, Zhao Y, Ma J, Xia T, Liu X, Ding Q, Zha X, Wang S. Hypoxia-induced factor-1 alpha upregulates vascular endothelial growth factor C to promote lymphangiogenesis and angiogenesis in breast cancer patients. J Biomed Res 2013; 27: 478-85.
24. Prigione A, Rohwer N, Hoffmann S, Mlody B, Drews K, Bukowiecki R, Blümlein K, Wanker EE, Ralser M, Cramer T, Adjaye J. HIF1α modulates cell fate reprogramming through early glycolytic shift and upregulation of PDK1-3 and PKM2. Stem Cells 2014; 32: 364-76.